(Q34340578)

English

K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

cholangiocarcinoma

0 references

1 reference

based on heuristic

inferred from title

intrahepatic cholangiocarcinoma

1 reference

based on heuristic

inferred from title

author name string

Tse-Ching Chen

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Yi-Yin Jan

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Ta-Sen Yeh

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Annals of Surgical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

19 Suppl 3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

S675-81

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Cholangiocarcinoma.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Survival analysis of intrahepatic cholangiocarcinoma after resection.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Initial presentation and management of hilar and peripheral cholangiocarcinoma: is a node-positive status or potential margin-positive result a contraindication to resection?

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Clinicopathologic studies on perineural invasion of bile duct carcinoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Lifestyle risk factors for intrahepatic stone: findings from a case-control study in an endemic area, Taiwan

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Genetics of biliary tract cancers and emerging targeted therapies

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Why doctors should worry about preemption

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Cholangiographic spectrum of intraductal papillary mucinous neoplasm of the bile ducts

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2224-7

21 January 2018

Identifiers

10.1245/S10434-012-2224-7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34340578&oldid=2196524978"